Skip to main content
ADHERIUM LIMITED logo

ADHERIUM LIMITED — Investor Relations & Filings

Ticker · ADR ISIN · AU000000ADR1 ASX Manufacturing
Open in API
Filings indexed 872 across all filing types
Latest filing 2022-06-13 Capital/Financing Update
Country AU Australia
Listing ASX ADR

About ADHERIUM LIMITED

https://www.adherium.com

Adherium Limited is a digital health company specializing in the development and commercialization of connected medical devices and software solutions for chronic respiratory management. The company's primary offering is the Hailie® platform, which consists of advanced sensors that attach to various inhaler medications to monitor usage and technique. These sensors transmit data via Bluetooth to a mobile application and a cloud-based portal, providing patients and healthcare providers with real-time insights into medication adherence and respiratory health trends. By facilitating remote patient monitoring and data-driven clinical decisions, Adherium aims to improve health outcomes for individuals living with asthma and chronic obstructive pulmonary disease (COPD). The platform is utilized by healthcare systems, pharmaceutical companies, and clinical research organizations to enhance patient engagement and optimize treatment efficacy.

Recent filings

Filing Released Lang Actions
Adherium signs UK distribution agreement with Helicon Health 2 pages 109.5KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new distribution agreement between Adherium Limited and Helicon Health. It discusses the strategic partnership, product details, and business development plans. There is no indication of financial results, regulatory filings, management changes, or other formal report types. The content is typical of a Capital/Financing Update as it relates to business development and partnership agreements that impact the company's growth and market presence. The document length is 4753 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-06-13 English
Adherium to support Avillion sponsored clinical study 3 pages 135.2KB
Regulatory Filings Classification · 95% confidence The document is an announcement by Adherium regarding a contract award to supply a medical device solution for a clinical study sponsored by Avillion. It discusses the nature of the contract, the expected revenue, and background information about the companies involved. There are no financial statements, regulatory filings, or detailed financial performance data. The document is a corporate announcement about a business development or contract win, not a financial report, earnings release, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is best classified as a general Regulatory Filing (RNS) because it is a regulatory announcement that does not fit into more specific categories.
2022-06-01 English
Adherium Senior Management Update 2 pages 109.2KB
Board/Management Information Classification · 95% confidence The document is an announcement from Adherium Limited about the appointment of a new Vice President of Quality, Regulatory and Clinical Affairs and the conclusion of an interim CFO assignment. It focuses on management changes and does not contain financial data, regulatory filings, or report publications. The content is clearly about senior management updates, which fits the category of Board/Management Information (MANG). The document length is 4657 characters, which is sufficient for a detailed announcement but does not include financial statements or other report types. Therefore, the appropriate classification is MANG with high confidence.
2022-05-29 English
Adherium Exhibiting at ATS 2022 2 pages 106.4KB
Regulatory Filings Classification · 95% confidence The document is an announcement about Adherium exhibiting at the 2022 American Thoracic Society International Conference. It describes the event, the company's products, and its market focus. There is no financial data, no report attached or referenced, no voting results, no management changes, no legal or regulatory filings, and no mention of earnings or capital activities. The document is a general corporate announcement related to marketing and investor relations but does not fit into any specific financial report category. Given the content and length (3152 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other categories.
2022-05-12 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 351.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report to 31 March 2022' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities. It references the ASX Listing Rule 4.7B, which mandates quarterly cash flow reporting for listed entities in Australia. The document includes actual financial data for the quarter ended 31 March 2022, such as cash on hand, receipts, payments, and other cash flow components. It also contains management commentary on business progress and regulatory milestones, but the primary content is the quarterly financial report with substantive financial data. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-04-28 English
Adherium Releases Next Gen Platform Integration Services 3 pages 249.9KB
Capital/Financing Update Classification · 85% confidence The document is an announcement from Adherium Limited about the release of new software integration tools for their respiratory platform. It discusses product development milestones, software features, and market progress but does not contain financial statements, earnings data, or regulatory filings. There is no indication of a report being attached or published, nor is this a certification or voting result. The content focuses on product and technology updates rather than financial or governance matters. Therefore, it fits best as a Capital/Financing Update (CAP) since it relates to product development and commercial strategy updates that could impact capital or financing indirectly, but it is not a direct financial report or earnings release. Confidence is high given the clear product and platform integration focus and absence of financial reporting elements.
2022-04-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.